GLAUCYLARA REIS GEOVANINI
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/13 - Laboratório de Genética e Cardiologia Molecular, Hospital das Clínicas, Faculdade de Medicina
LIM/13 - Laboratório de Genética e Cardiologia Molecular, Hospital das Clínicas, Faculdade de Medicina
5 resultados
Resultados de Busca
Agora exibindo 1 - 5 de 5
- Obstructive sleep apnea and its management in patients with atrial fibrillation: An International Collaboration of Sleep Apnea Cardiovascular Trialists (INCOSACT) global survey of practicing cardiologists(2022) FAULX, Michael D.; MEHRA, Reena; GEOVANINI, Glaucylara Reis; ANDO, Shin-ichi; ARZT, Michael; DRAGER, Luciano; FU, Michael; HOYOS, Camilla; HAI, Jo; HWANG, Juey-Jen; KARAOGUZ, Remzi; KIMOFF, John; LEE, Pei-Lin; MEDIANO, Olga; PATEL, Sanjay R.; PEKER, Yuksel; PEPIN, Jean Louis; SANCHEZ-DE-LA-TORRE, Manuel; SERIES, Frederic; STADLER, Stefan; STROLLO, Patrick; TAHRANI, A. A.; THUNSTROM, Erik; YAMAUCHI, Motoo; REDLINE, Susan; PHILLIPS, Craig L.Background: Among international cardiologists it is unclear whether equipoise exists regarding the benefit of diagnosing and managing obstructive sleep apnea (OSA) to improve atrial fibrillation (AF) outcomes and whether clinical practice and equipoise are linked. Methods: Between January 2019 and June 2020 we distributed a web-based 12-question survey regarding OSA and AF management to practicing cardiologists in 16 countries. Results: The United States, Japan, Sweden, and Turkey accounted for two-thirds of responses. 863 cardiologists responded; half were general cardiologists, a quarter electrophysiologists. Responses regarding treating OSA with CPAP to improve AF endpoints were mixed. 33% of respondents referred AF patients for OSA screening. OSA was diagnosed in 48% of referred patients and continuous positive airway pressure (CPAP) was prescribed for 59% of them. Nearly 70% of respondents believed randomized controlled trials (RCTs) of OSA treatment in AF patients were necessary and indicated willingness to contribute to such trials. Conclusions: There was no clinical equipoise among surveyed cardiologists; a majority expressed certainty that combined OSA and AF treatment is superior to AF treatment alone for improving AF outcomes. However, a minority of surveyed cardiologists referred AF patients for OSA testing, and while half of screened AF patients had OSA, CPAP was prescribed in little more than half of them, reflecting the view that better clinical trial evidence is needed to support this practice. Our results underscore the need for larger, multi-national prospective studies of OSA treatment and AF outcomes to inform more uniform society guideline recommendations.
- Poor sleep quality and lipid profile in a rural cohort (The Baependi Heart Study)(2019) GEOVANINI, Glaucylara Reis; LORENZI-FILHO, Geraldo; PAULA, Lilian K. de; OLIVEIRA, Camila Maciel; ALVIM, Rafael de Oliveira; BEIJAMINI, Felipe; NEGRAO, Andre Brooking; SCHANTZ, Malcolm von; KNUTSON, Kristen L.; KRIEGER, Jose Eduardo; PEREIRA, Alexandre CostaAim: To test the association between cardiometabolic risk factors and subjective sleep quality assessed by the Pittsburgh sleep quality index (PSQI), independent of obstructive sleep apnea (OSA) and sleep duration. Methods: A total of 573 participants from the Baependi Heart Study, a rural cohort from Brazil, completed sleep questionnaires and underwent polygraphy for OSA evaluation. Multivariable linear regression analysis tested the association between cardiovascular risk factors (outcome variables) and sleep quality measured by PSQI, adjusting for OSA and other potential confounders (age, sex, race, salary/wage, education, marital status, alcohol intake, obesity, smoking, hypertension, and sleep duration). Results: The sample mean age was 43 +/- 16 years, 66% were female, and mean body mass index (BMI) was 26 +/- 5 kg/m(2). Only 20% were classified as obese (BMI >= 30). Overall, 50% of participants reported poor sleep quality as defined by a PSQI score >= 5. A high PSQI score was significantly associated with higher very-low-density lipoprotein (VLDL) cholesterol levels (beta = 0.392, p = 0.012) and higher triglyceride levels (beta = 0.017, p = 0.006), even after adjustments, including the apneaehypopnea index. Further adjustments accounting for marital status, alcohol intake, and medication use did not change these findings. No significant association was observed between PSQI scores and glucose or blood pressure. According to PSQI components, sleep disturbances (beta = 1.976, p = 0.027), sleep medication use (beta = 1.121, p = 0.019), and daytime dysfunction (beta = 1.290, p = 0.024) were significantly associated with higher VLDL serum levels. Only the daytime dysfunction domain of the PSQI components was significantly associated with higher triglyceride levels (beta = 0.066, p = 0.004). Conclusion: Poorer lipid profile was independently associated with poor sleep quality, assessed by the PSQI questionnaire, regardless of a normal sleep duration and accounting for OSA and socio-economic status.
- 1st Brazilian Positioning on the Impact of Sleep Disorders on Cardiovascular Diseases of the Brazilian Society of Cardiology(2018) DRAGER, Luciano E.; LORENZI-FILHO, Geraldo; CINTRA, Fatima Dumas; PEDROSA, Rodrigo P.; BITTENCOURT, Lia R. A.; POYARES, Dalva; CARVALHO, Carolina Gonzaga; MOURA, Sonia Maria Guimaraes Pereira Togeiro; SANTOS-SILVA, Rogerio; BRUIN, Pedro F. C. de; GEOVANINI, Glaucylara R.; ALBUQUERQUE, Felipe N.; OLIVEIRA, Vvercules Antonio Alves de; MOREIRA, Gustavo A.; UENO, Linda Massako; NERBASS, Flavia Baggio; RONDON, Maria Urbana Pinto Brandao; BARBOSA, Fine Rozaria Ferreira; BERTOLAMI, Adriana; PAOLA, Angelo Amato Vincenzo de; MARQUES, Betania Braga Silva; RIZZI, Camila Futado; NEGRAO, Carlos Eduardo; UCHOA, Carlos Henrique Gomes; MAKI-NUNES, Cristiane; MARTINEZ, Denis; FERNANDEZ, Edmundo Arteaga; MAROJA, Fabrizio U.; ALMEIDA, Fernanda R.; TROMBETTA, Ivani C.; STORTI, Luciana J.; BORTOLOTTO, Luiz Aparecido; MELLO, Marco Tulio de; BORGES, Melania Aparecida; ANDERSEN, Monica Levy; PORTILHO, Natanael de Paula; MACEDO, Paula; ALVES, Rosana; TUFIK, Sergio; FAGONDES, Simone C.; RISSO, Thais Telles
- OSA and Prognosis After Acute Cardiogenic Pulmonary Edema The OSA-CARE Study(2017) UCHOA, Carlos Henrique G.; PEDROSA, Rodrigo P.; JAVAHERI, Shahrokh; GEOVANINI, Glaucylara R.; CARVALHO, Martinha M. B.; TORQUATRO, Ana Claudia S.; LEITE, Ana Paula D. L.; GONZAGA, Carolina C.; BERTOLAMI, Adriana; AMODEO, Celso; PETISCO, Ana Claudia G. P.; BARBOSA, Jose Eduardo M.; MACEDO, Thiago A.; BORTOLOTTO, Luiz A.; OLIVEIRA JR., Mucio Tavares; LORENZI-FILHO, Geraldo; DRAGER, Luciano F.BACKGROUND: Acute cardiogenic pulmonary edema (ACPE) is a life-threatening condition. OSA may be a modifiable risk factor for ACPE recurrence. This study was designed to evaluate the impact of OSA on the incidence of cardiovascular events following ACPE recovery. METHODS: Consecutive patients with confirmed ACPE from 3 centers underwent a sleep study following clinical stabilization. OSA was defined as an apnea-hypopnea index (AHI) >= 15 events/h. The mean follow-up was 1 year, and the primary outcome was ACPE recurrence. RESULTS: A total of 104 patients were included in the final analysis; 61% of the patients had OSA. A higher rate of ACPE recurrence (25 vs 6 episodes; P = .01) and a higher incidence of myocardial infarction (15 vs 0 episodes; P = .0004) were observed in patients with OSA than in those without OSA. All 17 deaths occurred in the OSA group (P = .0001). In a Cox proportional hazards regression analysis, OSA was independently associated with ACPE recurrence (hazard ratio [HR], 3.3 [95% CI, 1.2-8.8]; P = .01), incidence of myocardial infarction (HR, 2.3 [95% CI, 1.1-9.5]; P = .02), cardiovascular death (HR, 5.4 [95% CI, 1.4-48.4]; P = .004), and total death (HR, 6.5 [95% CI, 1.2-64.0]; P = .005). When the analysis was limited only to patients with OSA, levels of AHI and hypoxemic burden and rates of sleep-onset ACPE were significantly higher in those who presented with ACPE recurrence or who died than in those who did not experience these events. CONCLUSIONS: OSA is independently associated with higher rates of ACPE recurrence and both fatal and nonfatal cardiovascular events.
- Atherosclerosis and inflammation: overview and updates(2018) GEOVANINI, Glaucylara Reis; LIBBY, PeterThe concept that inflammation participates pivotally in the pathogenesis of atherosclerosis and its complications has gained considerable attention, but has not yet entered clinical practice. Experimental work has elucidated molecular and cellular pathways of inflammation that promote atherosclerosis. The recognition of atherogenesis as an active process rather than a cholesterol storage disease or a repository of calcium has highlighted some key inflammatory mechanisms. For example, mononuclear phagocytes contribute to all stages of this disease, illustrating the link between inflammation and atherosclerosis. From a clinical perspective, harnessing inflammation may now help target therapeutics, change guidelines, and enter daily practice. Multiple lines of incontrovertible evidence have proven a causal role for low-density lipoprotein (LDL) cholesterol in atherosclerosis, and we have highly effective tools for lowering LDL, consequently reducing events. Yet, even with intense LDL reduction, events still occur. Inflammation can explain some of this residual risk. An anti-inflammatory intervention has now proven capable of improving outcomes in individuals well treated with LDL-lowering agents. A suite of trials are now pursuing anti-inflammatory therapies in this context. Assessment and treatment of residual inflammatory risk are poised to provide new inroads into preventive cardiology. This brief review aims to explore the potential mechanisms underlying the association of inflammation and atherogenesis, and their clinical consequences.